Scilex Holding Presents Poster On ELYXYB At The Annual Scientific Meeting Of The AHS To Be Held On June 13-16, 2024

Author: Benzinga Newsdesk | June 13, 2024 09:13am

• Up to 60% of patients with migraine do not sufficiently respond to triptans.
• Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.
• In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB®-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3% vs. 14.3%, p=0.0036). The likelihood of achieving pain freedom was 200% greater with ELYXYB® than with placebo (OR=3.0).

Posted In: SCLX